Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Japanese Journal of Radiology
Erschienen in: Japanese Journal of Radiology 12/2015

01.12.2015 | Review

Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma

verfasst von: Kazuhiro Kitajima, Yuko Suenaga, Kazuro Sugimura

Erschienen in: Japanese Journal of Radiology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-d-glucose (FDG) is a useful technique for acquisition of both glucose metabolic and anatomic imaging data using a single device in a single diagnostic session, and has opened a new field in clinical oncologic imaging. FDG-PET/CT has been used successfully for the initial staging, restaging, monitoring of the response to therapy, and prognostication of head and neck carcinoma. The present review discusses the current role of FDG-PET/CT in the management of head and neck carcinoma, focusing on its usefulness and limitations for imaging in these patients.
Literatur
1.
2.
Fleming AJ Jr, Smith SP Jr, Paul CM, Hall NC, Daly BT, Agrawal A, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007;117:1173–9.PubMedCrossRef
3.
Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg. 2007;137:130–7.PubMedCrossRef
4.
Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986–95.PubMedCrossRef
5.
Veit-Haibach P, Luczak C, Wanke I, Fischer M, Egelhof T, Beyer T, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging. 2007;34:1953–62.PubMedCrossRef
6.
Kim SY, Roh JL, Yeo NK, Kim JS, Lee JH, Choi SH, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol. 2007;18:1698–703.PubMedCrossRef
7.
Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, et al. Head and neck squamous cell carcinoma (HNSCC)—detection of synchronous primaries with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:919–27.PubMedCrossRef
8.
Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol ( Coll Radiol. 2013;25:e33–66.CrossRef
9.
Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol. 2010;28:1190–5.PubMedCrossRef
10.
Becker M, Zbären P, Casselman JW, Kohler R, Dulguerov P, Becker CD. Neoplastic invasion of laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging. Radiology. 2008;249:551–9.PubMedCrossRef
11.
Becker M, Burkhardt K, Dulguerov P, Allal A. Imaging of the larynx and hypopharynx. Eur J Radiol. 2008;66:460–79.PubMedCrossRef
12.
Paes FM, Singer AD, Checkver AN, Palmquist RA, De La Vega G, Sidani C. Perineural spread in head and neck malignancies: clinical significance and evaluation with 18F-FDG PET/CT. Radiographics. 2013;33:1717–36.PubMedCrossRef
13.
Snow GB, Patel P, Leemans CR, Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol. 1992;249:187–94.PubMedCrossRef
14.
Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg. 1990;160:405–9.PubMedCrossRef
15.
Castelijins JA, van den Brekel MW. Imaging of lymphadenopathy in the neck. Eur Radiol. 2002;12:727–38.CrossRef
16.
Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, et al. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation. J Nucl Med. 2005;46:1136–43.PubMed
17.
Schöder H, Carlson DL, Kraus DH, Stambuk HE, Gönen M, Erdi YE, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med. 2006;47:755–62.PubMed
18.
Murakami R, Uozumi H, Hirai T, Nishimura R, Shiraishi S, Ota K, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2007;68:377–82.PubMedCrossRef
19.
Jeong HS, Baek CH, Son YI, Ki Chung M, Kyung Lee D, Young Choi J, et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck. 2007;29:203–10.PubMedCrossRef
20.
Nabmias C, Carlson ER, Duncan LD, Blodgett TM, Kennedy J, Long MJ, et al. Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. J Oral Maxillofac Surg. 2007;65:2524–35.CrossRef
21.
Roh JL, Yeo NK, Kim JS, Lee JH, Cho KJ, Choi SH, et al. Utility of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol. 2007;43:887–93.PubMedCrossRef
22.
Yamazaki Y, Saitoh M, Notani K, Tei K, Totsuka Y, Takinami S, et al. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med. 2008;22:177–84.PubMedCrossRef
23.
Krabbe CA, Dijkstra PU, Pruim J, van der Laan BF, van der Wal JE, Gravendeel JP, et al. FDG PET in oral and oropharyngeal cancer. Value for confirmation of N0 neck and detection of occult metastases. Oral Oncol. 2008;44:31–6.PubMedCrossRef
24.
Piao Y, Bold B, Tayier A, Ishida R, Omura K, Okada N, et al. Evaluation of 18F-FDG PET/CT for diagnosing cervical nodal metastases in patients with oral cavity or oropharynx carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:933–8.PubMedCrossRef
25.
Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, et al. CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol. 2009;19:634–42.PubMedCrossRef
26.
Richard C, Prevot N, Timoshenko AP, Dumollard JM, Dubois F, Martin C, et al. Preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography imaging in head and neck cancer: does it really improve initial N staging? Acta Otolaryngol. 2010;130:1421–4.PubMedCrossRef
27.
Iyer NG, Clark JR, Singham S, Zhu J. Role of pretreatment 18FDG-PET/CT in surgical decision-making for head and neck cancers. Head Neck. 2010;32:1202–8.PubMedCrossRef
28.
Kim SY, Kim JS, Doo H, Lee H, Lee JH, Cho KJ, et al. Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography for detecting contralateral neck metastases in patients with head and neck squamous cell carcinoma. Oral Oncol. 2011;47:376–80.PubMedCrossRef
29.
Matsubara R, Kawano S, Chikui T, Kiyosue T, Goto Y, Hirano M, et al. Clinical significance of combined assessment of the maximum standardized uptake value of F-18 FDG PET with nodal size in the diagnosis of cervical lymph node metastasis of oral squamous cell carcinoma. Acad Radiol. 2012;19:708–17.PubMedCrossRef
30.
Nguyen A, Luginbuhl A, Cognetti D, Van Abel K, Bar-Ad V, Intenzo C, et al. Effectiveness of PET/CT in the preoperative evaluation of neck disease. Laryngoscope. 2014;124:159–64.PubMedCrossRef
31.
Roh JL, Park JP, Kim JS, Lee JH, Cho KJ, Choi SH, et al. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study. Radiology. 2014;271:153–61.PubMedCrossRef
32.
Joo YH, Yoo IR, Cho KJ, Park JO, Nam IC, Kim CS, et al. The value of preoperative 18F-FDG PET/CT for assessing the contralateral neck in head and neck cancer patients with unilateral node metastasis (N1-3). Clin Otolaryngol. 2014;39:338–44.PubMedCrossRef
33.
Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst. 2008;100:712–20.PubMedCrossRef
34.
Sun R, Tang X, Yang Y, Zhang C. 18FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol. 2015;51:314–20.PubMedCrossRef
35.
Xu GZ, Zhu XD, Li MY. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head Neck. 2011;33:87–94.PubMedCrossRef
36.
Jereczek-Fossa BA, Jassem J, Orecchia R. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev. 2004;30:153–64.PubMedCrossRef
37.
Yabuki K, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G. Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol. 2010;267:1785–92.PubMedCrossRef
38.
Wong WL, Sonoda LI, Gharpurhy A, Gollub F, Wellsted D, Goodchild K, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers—an audit and review of published studies. Clin Oncol R Coll Radiol. 2012;24:190–5.PubMedCrossRef
39.
Lee JR, Kim JS, Roh JL, Lee JH, Baek JH, Cho KJ, et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of 18F FDG PET/CT with contrast-enhanced CT or CT/MR imaging—prospective study. Radiology. 2015;274:764–71.PubMedCrossRef
40.
Van Rees BP, Cleton-Jansen AM, Cense HA, Polak MM, Clement MJ, Drillenburg P, et al. Molecular evidence of field cancerization in a patient with 7 tumors of the aerodigestive tract. Hum Pathol. 2000;31:269–71.PubMedCrossRef
41.
Su YY, Fang FM, Chuang HC, Luo SD, Chien CY. Detection of metachronous esophageal squamous carcinoma in patients with head and neck cancer with use of transnasal esophagoscopy. Head Neck. 2010;32:780–5.PubMed
42.
Nakaminato S, Toriihara A, Makino T, Kawano T, Kishimoto S, Shibuya H. Prevalence of esophageal cancer during the pretreatment of hypopharyngeal cancer patients: routinely performed esophagogastroduodenoscopy and FDG-PET/CT findings. Acta Oncol. 2012;51:645–52.PubMedCrossRef
43.
Xu GZ, Guan DJ, He ZY. 18FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. Oral Oncol. 2011;47:560–5.PubMedCrossRef
44.
Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571–8.PubMedCrossRef
45.
Lell M, Baum U, Greess H, Nömayr A, Nkenke E, Koester M, et al. Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol. 2000;33:239–47.PubMedCrossRef
46.
Salaun PY, Abgral R, Querellou S, Couturier O, Valette G, Bizais Y, et al. Does 18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck. 2007;29:1115–20.PubMedCrossRef
47.
Branstetter BF 4th, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005;235:580–6.PubMedCrossRef
48.
Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645–50.PubMedCrossRef
49.
Nayak JV, Walvekar RR, Andrade RS, Daamen N, Lai SY, Argiris A, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope. 2007;117:2129–34.PubMedCrossRef
50.
Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007;62:199–204.PubMedCrossRef
51.
Kim SY, Lee SW, Nam SY, Im KC, Kim JS, Oh SJ, et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med. 2007;48:373–8.PubMed
52.
Lee JC, Kim JS, Lee JH, Nam SY, Choi SH, Lee SW, et al. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma. Oral Oncol. 2007;43:686–92.PubMedCrossRef
53.
Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology. 2008;249:203–11.PubMedCrossRef
54.
Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532–40.PubMedCrossRef
55.
Krabbe CA, Pruim J, Dijkstra PU, Balink H, van der Laan BF, de Visscher JG, et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med. 2009;50:1940–7.PubMedCrossRef
56.
Rabalais AG, Walvekar R, Nuss D, McWhorter A, Wood C, Fields R, et al. Positron emission tomography-computed tomography surveillance for the node-positive neck after chemoradiotherapy. Laryngoscope. 2009;119:1120–4.PubMedCrossRef
57.
Gourin CG, Watts T, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope. 2009;119:703–6.PubMedCrossRef
58.
Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer. 2009;115:4586–94.PubMedCrossRef
59.
Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50:24–9.PubMedCrossRef
60.
Yao M, Smith RB, Hoffman HT, Funk GF, Lu M, Menda Y, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer—a long-term outcome report. Int J Radiat Oncol Biol Phys. 2009;74:9–14.PubMedCrossRef
61.
Kim SY, Kim JS, Yi JS, Lee JH, Choi SH, Nam SY, et al. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma. Ann Surg Oncol. 2011;18:2579–84.PubMedCrossRef
62.
Zundel MT, Michel MA, Schultz CJ, Maheshwari M, Wong SJ, Campbell BH, et al. Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography 4–6 months after radiotherapy to assess residual head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81:e825–32.PubMedCrossRef
63.
Zhang I, Branstetter BF 4th, Beswick DM, Maxwell JH, Gooding WE, Ferris RL. The benefit of early PET/CT surveillance in HPV-associated head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2011;137:1106–11.PubMedCrossRef
64.
Yi JS, Kim JS, Lee JH, Choi SH, Nam SY, Kim SY, et al. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma. J Surg Oncol. 2012;106:708–12.PubMedCrossRef
65.
Beswick DM, Gooding WE, Johnson JT, Branstetter BF 4th. Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Laryngoscope. 2012;122:1512–7.PubMedPubMedCentralCrossRef
66.
Kostakoglu L, Fardanesh R, Posner M, Som P, Rao S, Park E, et al. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist. 2013;18:1108–17.PubMedPubMedCentralCrossRef
67.
Ho AS, Tsao GJ, Chen FW, Shen T, Kaplan MJ, Colevas AD, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer. 2013;119:1349–56.PubMedCrossRef
68.
Rangaswamy B, Fardanesh MR, Genden EM, Park EE, Fatterpekar G, Patel Z, et al. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination. Laryngoscope. 2013;123:2664–9.PubMedCrossRef
69.
Dunsky KA, Wehrmann DJ, Osman MM, Thornberry BM, Varvares MA. PET-CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patient. Laryngoscope. 2013;123:2161–4.PubMedCrossRef
70.
Kim JW, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, et al. 18F-FDG PET/CT surveillance at 3–6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer. 2013;109:2973–9.PubMedPubMedCentralCrossRef
71.
Koshkareva Y, Branstetter BF 4th, Gaughan JP, Ferris RL. Predictive accuracy of first post-treatment PET/CT in HPV-related oropharyngeal squamous cell carcinoma. Laryngoscope. 2014;124:1843–7.PubMedCrossRef
72.
Robin P, Abgral R, Valette G, Le Roux PY, Keromnes N, Rousset J, et al. Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. Eur J Nucl Med Mol Imaging. 2015;42:72–8.PubMedCrossRef
73.
Suenaga Y, Kitajima K, Ishihara T, Sasaki R, Otsuki N, Nibu KI, et al. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT. Eur Radiol. 2015 [Epub ahead of print].
74.
Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow-up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210–22.PubMedCrossRef
75.
Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–95.PubMedCrossRef
76.
Kawabe J, Higashiyama S, Yoshida A, Kotani K, Shiomi S. The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients. Jpn J Radiol. 2012;30:463–70.PubMedCrossRef
77.
Paidpally V, Tahari AK, Lam S, Alluri K, Marur S, Koch W, et al. Addition of 18F-FDG PET/CT to clinical assessment predicts overall survival in HNSCC: a retrospective analysis with follow-up for 12 years. J Nucl Med. 2013;54:2039–45.PubMedCrossRef
78.
Gao S, Li S, Yang X, Tang Q. 18FDG PET-CT for distant metastases in patients with recurrent head and neck cancer after definitive treatment. A meta-analysis. Oral Oncol. 2014;50:163–7.PubMedCrossRef
79.
Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011;33:1675–82.PubMedCrossRef
80.
Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective risk-adjusted [18F]fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509–15.PubMedPubMedCentralCrossRef
81.
Kitagawa Y, Nishizawa S, Sano K, Ogasawara T, Nakamura M, Sadato N, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67 Ga scintigraphy) in assessment of combined intra-arterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med. 2003;44:198–206.PubMed
82.
Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315–22.PubMedCrossRef
83.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Eng J Med. 2003;349:2091–8.CrossRef
84.
Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–35.PubMedCrossRef
85.
Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N. Usefulness of 3′-deoxy-3′-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med. 2012;53:1521–7.PubMedCrossRef
86.
Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and l-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8.PubMed
87.
Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-d-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–300.PubMedCrossRef
88.
Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB, et al. 2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol. 2007;33:790–5.PubMedCrossRef
89.
Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31:195–201.PubMedCrossRef
90.
Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Naitou K, Ueda Y, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol. 2009;192:W156–60.PubMedCrossRef
91.
Suzuki K, Nishioka T, Homma A, Tsuchiya K, Yasuda M, Aoyama H, et al. Value of fluorodeoxyglucose positron emission tomography before radiotherapy for head and neck cancer: does the standardized uptake value predict treatment outcome? Jpn J Radiol. 2009;27:237–42.PubMedCrossRef
92.
Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol. 2010;130:756–62.PubMedCrossRef
93.
Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:1514–20.PubMedPubMedCentralCrossRef
94.
Demirci U, Coskun U, Akdemir UO, Benekli M, Kapucu O, Ozkan S, et al. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer. Asian Pac J Cancer Prev. 2011;12:1817–20.PubMed
95.
Inokuchi H, Kodaira T, Tachibana H, Nakamura T, Tomita N, Nakahara R, et al. Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys. 2011;79:747–55.PubMedCrossRef
96.
Kubicek GJ, Champ C, Fogh S, Wang F, Reddy E, Intenzo C, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol. 2010;16:19–25.CrossRef
97.
Kitajima K, Suenaga Y, Kanda T, Miyawaki D, Yoshida K, Ejima Y, et al. Prognostic value of FDG PET imaging in patients with laryngeal cancer. PLoS One. 2014;9(5):e96999.PubMedPubMedCentralCrossRef
98.
Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989–96.PubMedCrossRef
99.
Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDGPET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med. 2012;4:633–47.PubMedPubMedCentralCrossRef
100.
Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.PubMedCrossRef
101.
Park GC, Kim JS, Roh JL, Choi SH, Nam SY, Kim SY. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol. 2013;24:208–24.PubMedCrossRef
102.
Abd El-Hafez YG. Moustafa HM, Khalil HF, Liao CT, Yen TC. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol. 2013;49:261–8.PubMedCrossRef
103.
Chang KP, Tsang NM, Liao CT, Hsu CL, Chung MJ, Lo CW, et al. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. J Nucl Med. 2012;53:21–8.PubMedCrossRef
104.
Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55:884–90.PubMedCrossRef
105.
Goldenberg D, Begum S, Westra WH, Khan Z, Sciubba J, Pai SI, et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck. 2008;30:898–903.PubMedCrossRef
106.
Subramaniam RM, Alluri KC, Tahari AK, Aygun N, Quon H. PET/CT imaging and human papilloma virus-positive oropharyngeal squamous cell cancer: evolving clinical imaging paradigm. J Nucl Med. 2014;55:431–8.PubMedCrossRef
Metadaten
Titel
Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma
verfasst von
Kazuhiro Kitajima
Yuko Suenaga
Kazuro Sugimura
Publikationsdatum
01.12.2015
Verlag
Springer Japan
Erschienen in
Japanese Journal of Radiology / Ausgabe 12/2015
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-015-0495-1

Weitere Artikel der Ausgabe 12/2015

Japanese Journal of Radiology 12/2015 Zur Ausgabe

Case Report

Congenital anomaly of combined atlas-odontoid process fusion and bipartite atlas

Original Article

The phrenic nerve with accompanying vessels: a silent cause of cardiovascular border obliteration on chest radiography

Technical Note

Creation of small gelatin particles by pumping method for transarterial chemoembolization of hepatocellular carcinoma: analysis of particle size and reproducibility

Case Report

Bilateral duplication of the abducens nerves: an incidental finding on magnetic resonance imaging

Original Article

Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres

Case Report

Intramural esophageal dissection diagnosed on transabdominal ultrasonography

Neu im Fachgebiet Radiologie

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise